Brief: 4Dmt Acquires Complement Pathway Inhibitor Payload For 4D-175 Product Candidate For Geographic Atrophy
24/04/2023 13:22
April 24 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT ACQUIRES COMPLEMENT PATHWAY INHIBITOR PAYLOAD FOR
4D-175
PRODUCT CANDIDATE FOR GEOGRAPHIC ATROPHY
* 4D MOLECULAR THERAPEUTICS INC - ACQUIRED RIGHTS AND
KNOW-HOW FOR
SHORT-FORM HUMAN COMPLEMENT FACTOR H (SCFH) FROM AEVITAS
THERAPEUTICS
Source text for Eikon: ID:nGNXb8njLD
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings